Transformed Lymphoma: Clinical Trials

7 trials for Transformed Lymphoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 unknown, 2 recruiting, 1 active not recruiting, 1 completed. 7 Phase 1, 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 17Unknown 3, Recruiting 2, Active not recruiting 1, Completed 1
Phase 24Unknown 3, Recruiting 1

Follow Transformed Lymphoma: new trials by email Literature Review of Transformed Lymphoma trials Research Report on Transformed Lymphoma

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma
Acalabrutinib - Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma
Phase 1 / Phase 2RecruitingJonsson Comprehensive Cancer Center242023-01-232026-03-10
Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma
Mosunetuzumab - B Cell Lymphoma, Aggressive Lymphoma
Phase 1Active not recruitingWashington University School of Medicine92022-12-222026-10-13
Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL
PD-1 Antibody, Lenalidomide - Non-GCB/ABC Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma
Phase 1 / Phase 2UnknownHuiqiang Huang302021-03-312021-03-15
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
Fludarabine, Cyclophosphamide, anti-CD19 CAR-T cells - Refractory Non-Hodgkin Lymphoma, Burkitt Lymphoma
Phase 1RecruitingC. Babis Andreadis362020-09-112026-10-26
Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL
Camrelizumab, Apatinib - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
Phase 1 / Phase 2UnknownHuiqiang Huang332020-07-232021-03-15
Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma
Toripalimab, Rituximab, R-CHOP Protocol - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
Phase 1 / Phase 2UnknownHuiqiang Huang1402020-04-242022-04-14
Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma
BZ019 - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
Phase 1CompletedInstitute of Hematology & Blood Diseases Hospital, China122018-06-082026-02-11

Narrower conditions

Lymphoma, Large B-Cell, Diffuse (6)  ·  Pyloric Stenosis, Hypertrophic (3)  ·  Lymphoma, Follicular (2)  ·  Recurrence (2)  ·  Burkitt Lymphoma (1)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (1)  ·  Lymphoma, B-Cell (1)  ·  Lymphoma, B-Cell, Marginal Zone (1)  ·  Lymphoma, Mantle-Cell (1)  ·  Lymphoma, Non-Hodgkin (1)

Broader conditions

Hemic and Lymphatic Diseases (6)  ·  Immune System Diseases (6)  ·  Immunoproliferative Disorders (6)  ·  Lymphatic Diseases (6)  ·  Lymphoma (6)  ·  Lymphoproliferative Disorders (6)  ·  Neoplasms (6)  ·  Neoplasms by Histologic Type (6)  ·  Lymphoma, B-Cell (5)  ·  Lymphoma, Non-Hodgkin (5)  ·  Digestive System Diseases (3)  ·  Disease Attributes (3)  ·  Gastric Outlet Obstruction (3)  ·  Gastrointestinal Diseases (3)  ·  Pathologic Processes (3)

Interventions

Automobiles (1)  ·  Cyclophosphamide (1)  ·  Immunotherapy, Adoptive (1)  ·  Lenalidomide (1)  ·  R-CHOP protocol (1)  ·  Rituximab (1)  ·  Therapeutics (1)  ·  acalabrutinib (1)  ·  apatinib (1)  ·  camrelizumab (1)  ·  fludarabine (1)  ·  fludarabine phosphate (1)  ·  spartalizumab (1)  ·  tislelizumab (1)  ·  toripalimab (1)

Sponsors

Huiqiang Huang (3)  ·  C. Babis Andreadis (1)  ·  Institute of Hematology & Blood Diseases Hospital, China (1)  ·  Jonsson Comprehensive Cancer Center (1)  ·  Washington University School of Medicine (1)

Countries

China (4)  ·  United States (3)

Top investigators

Armin Ghobadi, M.D. (1)  ·  Carrie Ho, MD (1)  ·  Caspian Oliai, MD (1)  ·  Huiqiang Huang, Professor (1)  ·  Lugui Qiu, MD (1)

Results publications

PMID 34515338